NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ADVIL DUAL ACTION WITH ACETAMINOPHEN (ibuprofen, acetaminophen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2020.
Drug data last refreshed 43m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL DUAL ACTION WITH ACETAMINOPHEN is an oral tablet combining ibuprofen (a cyclooxygenase inhibitor) and acetaminophen for synergistic pain and fever relief. The dual-mechanism formulation targets inflammation and pain through complementary pathways. It is indicated for general pain management in adult populations.
Peak14.7 years to LOE
Product is in peak revenue stage with stable market presence; OTC positioning limits team size compared to Rx brands.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ADVIL DUAL ACTION offers exposure to OTC marketing strategy, retail partnerships, and mass-market consumer engagement in a stable, established product. Career progression is incremental; advancement depends on consumer sales growth and cross-functional category leadership rather than clinical or regulatory milestones.
Brand Manager
Worked on ADVIL DUAL ACTION WITH ACETAMINOPHEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.